Actuate Therapeutics, Inc. Common stock
ACTUHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Actuate Therapeutics, Inc. Common stock (ACTU) is listed under Biotechnology. At a $11.4M market cap, Actuate Therapeutics, Inc. Common stock ranks as a micro-cap company within healthcare. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
Market Cap
$11.4M
Beta
1.20
P/E (TTM)
—
P/E (Fwd)
-0.72
EPS (TTM)
$-0.80
EPS (Fwd)
$-0.66
ROE
—
ROA
-213.4%
Cash
$4.4M
Total Debt
$0
Free CF
-$12.5M
52W Change
-93.5%
Annual Financials
Cash vs Debt
Where ACTU stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ACTU finished 64.91% below its 150-day moving average ($1.71) and 75.10% below its 200-day moving average ($2.41). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ACTU overbought or oversold?
At the October 20, 2026 close, ACTU's RSI(14) was 45.7, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Actuate Therapeutics, Inc. Common stock reports $4.4M in cash and $0 in total debt. Free cash flow is running at -$12.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ACTU's risk profile alongside its fundamentals and technical indicators provides a more complete picture.